Skip to main content

Table 1 Patient characteristics and prevalence of circulating tumor cells at baseline ( n= 147)

From: Circulating tumor cells in newly diagnosed inflammatory breast cancer

  Stage III IBC Metastatic IBC
Characteristic N % ≥1 CTC a % 5 CTC a % N % 1 CTC a % 5 CTC a %
All patients 77 100.0 42 54.5 15 19.5 70 100.0 59 84.3 32 45.7
Histology             
Infiltrative ductal carcinoma 74 96.1 40 54.1 15 20.3 66 94.3 55 83.3 31 47.0
Other histology 3 3.9 2 66.7 0 0.00 4 5.7 4 100.0 1 25.0
P value     1.00   0.61     0.61   0.62
ER/PR status             
Positive for either 43 55.8 19 44.2 5 11.6 40 57.1 33 82.5 20 50.0
Negative for both 34 44.2 23 67.6 10 29.4 30 42.9 26 86.7 12 40.0
P value     0.06   0.08     0.74   0.47
HER-2/neu status             
Overexpressed 26 33.8 17 65.4 7 26.9 19 27.1 13 68.4 9 47.4
Negative 51 66.2 25 49.0 8 15.7 51 72.9 46 90.2 23 45.1
P value     0.23   0.36     0.04   1.00
Grade             
High grade 55 71.4 32 58.2 11 20.0 53 75.7 43 81.1 24 45.3
Intermediate/low grade 22 28.6 10 45.5 4 18.2 15 21.4 14 93.3 8 53.3
Unknown - - - - - - 2 2.9 2 - 0 -
P value     0.31   1.00     0.43   0.77
ER/PR and HER2/neu status             
Triple receptor negative 19 24.7 12 63.2 5 26.3 19 27.1 17 89.5 7 36.8
Not-triple receptor negative 58 75.3 30 51.7 10 17.2 51 72.9 42 82.4 25 49.0
P value     0.44   0.50     0.71   0.43
Sites of metastases             
Non-visceral - - - - - - 42 60.0 34 81.0 18 42.9
Visceral - - - - - - 28 40.0 25 89.3 14 50.0
P value           0.50   0.63
Bone metastasis             
Present - - - - - - 39 55.7 32 82.1 19 48.7
Absent - - - - - - 31 44.3 27 87.1 13 41.9
P value           0.70   0.63
Number of metastases             
1 - - - - - - 29 41.4 22 75.9 13 44.8
≥2 - - - - - - 41 58.6 37 90.2 19 46.3
P value           0.20   1.00
Statin use             
No-statins 62 80.5 39 62.9 14 22.6 60 85.7 51 85.0 30 50.0
L-statinsb 7 9.1 1 14.3 1 14.3 5 7.1 5 100.0 1 20.0
H-statinsb 8 10.4 2 25.0 0 0.0 5 7.1 3 60.0 1 20.0
P value     0.01   0.30     0.20   0.21
Menopausal status             
Premenopausal 27 35.1 19 70.4 9 33.3 25 35.7 21 84.0 13 52.0
Postmenopausal 50 64.9 23 46.0 6 12.0 45 64.3 38 84.4 19 42.2
P value     0.06   0.03     1.00   0.46
Lymphovascular tumor emboli             
Present 36 46.8 20 55.6 9 25.0 42 60.0 37 88.1 17 40.5
Absent 40 51.9 21 52.5 6 15.0 24 34.3 18 75.0 12 50.0
Unknown 1 1.3 1 - 0 - 4 5.7 4 - 3 -
P value     0.64   0.39     0.19   0.61
  1. ER, estrogen receptor; PR, progesterone receptor.
  2. aPer 7.5 ml of whole peripheral blood.
  3. bLipophilic statins were classified as L-statins, and weakly lipophilic to hydrophilic statins were classified as H-statins.